NASDAQ:AGTC - Applied Genetic Technologies Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.10 +0.10 (+2.50 %) (As of 08/21/2018 11:55 AM ET)Previous Close$4.05Today's Range$4.05 - $4.1052-Week Range$3.25 - $5.75Volume400 shsAverage Volume75,171 shsMarket Capitalization$75.16 millionP/E Ratio200.00Dividend YieldN/ABeta2.1 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida. Receive AGTC News and Ratings via Email Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:AGTC CUSIPN/A Webwww.agtc.com Phone386-462-2204 Debt Debt-to-Equity RatioN/A Current Ratio6.61 Quick Ratio6.61 Price-To-Earnings Trailing P/E Ratio200.00 Forward P/E Ratio-3.94 P/E GrowthN/A Sales & Book Value Annual Sales$39.47 million Price / Sales1.88 Cash Flow$0.0720 per share Price / Cash56.98 Book Value$6.38 per share Price / Book0.64 Profitability EPS (Most Recent Fiscal Year)$0.02 Net Income$400,000.00 Net Margins-65.96% Return on Equity-16.00% Return on Assets-13.16% Miscellaneous Employees72 Outstanding Shares18,110,000Market Cap$75.16 million Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions What is Applied Genetic Technologies' stock symbol? Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC." How were Applied Genetic Technologies' earnings last quarter? Applied Genetic Technologies Corp (NASDAQ:AGTC) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.04. The biotechnology company earned $3.60 million during the quarter, compared to analysts' expectations of $6.41 million. Applied Genetic Technologies had a negative return on equity of 16.00% and a negative net margin of 65.96%. View Applied Genetic Technologies' Earnings History. When is Applied Genetic Technologies' next earnings date? Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, September, 12th 2018. View Earnings Estimates for Applied Genetic Technologies. What price target have analysts set for AGTC? 5 analysts have issued twelve-month price targets for Applied Genetic Technologies' stock. Their predictions range from $7.00 to $12.00. On average, they expect Applied Genetic Technologies' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 119.5% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies. What is the consensus analysts' recommendation for Applied Genetic Technologies? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies. What are Wall Street analysts saying about Applied Genetic Technologies stock? Here are some recent quotes from research analysts about Applied Genetic Technologies stock: 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (7/10/2018) 2. Cantor Fitzgerald analysts commented, "Natural history data from imaging 41 patients with CNGB3-associated achromatopsia (ACHM B3) between 6 and 26 months was published in the journel Retina journal today, suggest functional endpoints for evaluating efficacy." (10/6/2017) Who are some of Applied Genetic Technologies' key competitors? Some companies that are related to Applied Genetic Technologies include Surface Oncology (SURF), ADMA Biologics (ADMA), MeiraGTx (MGTX), Nantkwest (NK), Jounce Therapeutics (JNCE), Idera Pharmaceuticals (IDRA), Allena Pharmaceuticals (ALNA), Agenus (AGEN), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Eiger Biopharmaceuticals (EIGR), Krystal Biotech (KRYS), Organovo (ONVO), Pluristem Therapeutics (PSTI) and Cidara Therapeutics (CDTX). Who are Applied Genetic Technologies' key executives? Applied Genetic Technologies' management team includes the folowing people: Ms. Susan B. Washer, Pres, CEO & Director (Age 57)Dr. Mark S. Shearman Ph.D., Chief Scientific Officer (Age 58)Mr. Stephen W. Potter, VP & Chief Bus. Officer (Age 62)Dr. Nicholas Muzyczka, Co-FounderDr. Barry J. Byrne, Co-Founder Has Applied Genetic Technologies been receiving favorable news coverage? News coverage about AGTC stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Applied Genetic Technologies. Who are Applied Genetic Technologies' major shareholders? Applied Genetic Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.04%), Acadian Asset Management LLC (3.79%), Renaissance Technologies LLC (3.50%), BlackRock Inc. (1.84%), Municipal Employees Retirement System of Michigan (1.33%) and Point72 Asset Management L.P. (1.18%). Company insiders that own Applied Genetic Technologies stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies. Which institutional investors are selling Applied Genetic Technologies stock? AGTC stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Municipal Employees Retirement System of Michigan, BlackRock Inc. and Alambic Investment Management L.P.. View Insider Buying and Selling for Applied Genetic Technologies. Which institutional investors are buying Applied Genetic Technologies stock? AGTC stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Marquette Asset Management LLC and Point72 Asset Management L.P.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies. How do I buy shares of Applied Genetic Technologies? Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Applied Genetic Technologies' stock price today? One share of AGTC stock can currently be purchased for approximately $4.10. How big of a company is Applied Genetic Technologies? Applied Genetic Technologies has a market capitalization of $75.16 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe. How can I contact Applied Genetic Technologies? Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204. MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 300 (Vote Outperform)Underperform Votes: 172 (Vote Underperform)Total Votes: 472MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?